Clinical Trial Update: Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 0.05% Ingenol Mebutate (Picato 500) for treatment of basal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Picato 500 (ingenol mebutate)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Carcinoma | Phase 2 | Status: COMPLETED